Home › Peptides › PT-141 (Bremelanotide)

PT-141 (Bremelanotide) dosage and protocol

Libido-enhancing peptide that works on the nervous system for sexual arousal in both men and women

  • Vial size: 10 mg
  • Reconstitution: 3 mL bacteriostatic water
  • Concentration: 3.33 mg/mL
  • Administration: subcutaneous

Research areas

  • Sexual Enhancement
  • Libido
  • Erectile Function
  • Female Sexual Dysfunction

Quick start

  • Reconstitute: Add 3.0 mL bacteriostatic water to the 10 mg vial for about 3.33 mg/mL
  • Typical dose: 1-4 mg as needed, 45-60 minutes before activity (approved dose is 1.75 mg)
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL = 33.3 mcg on a U-100 syringe; 1 mg is 30 units and 1.75 mg is about 52.5 units
  • Storage: Unreconstituted at -20°C; refrigerate after mixing

Dosing protocol

PhaseDoseFrequencyVolume
Standard1000-400045-60 mins before intercourse0.2-0.8

How it works

PT-141, known clinically as bremelanotide, is a cyclic heptapeptide derived from melanotan II. It activates melanocortin receptors, mainly MC4R and MC3R, in the hypothalamus. Rather than acting on blood flow like PDE5 inhibitors, it is thought to influence central pathways for sexual motivation, including increasing dopamine release in the medial preoptic area. Bremelanotide is FDA-approved (as Vyleesi, 2019) for premenopausal women with acquired, generalised hypoactive sexual desire disorder not caused by another condition or medication. The approved regimen is 1.75 mg by subcutaneous autoinjector at least 45 minutes before anticipated sexual activity, no more than one dose in 24 hours and no more than eight doses per month. In the phase 3 RECONNECT trials it produced statistically significant but modest improvements in desire and a reduction in related distress compared with placebo. Earlier phase 2 work in men with erectile dysfunction, including some who did not respond to sildenafil, showed erectile responses, but development for men did not proceed to approval. Nausea was the most common side effect in the women's trials, and transient blood pressure increases led to a recommendation against use in uncontrolled hypertension or cardiovascular disease.

Reconstitution steps

  • Draw 2.0 mL bacteriostatic water with a sterile syringe
  • Inject slowly down the vial wall; avoid foaming
  • Gently swirl/roll until dissolved (do not shake)
  • Label with reconstitution date and refrigerate at 2–8°C, protected from light; use within 30 days

Storage

Store unreconstituted at -20°C. Refrigerate after mixing

Important notes

  • Derived from Melanotan II
  • Works on MC3R and MC4R in hypothalamus for CNS arousal
  • Take 45-60 minutes before intercourse
  • Effects last 24-72 hours
  • Maximum one dose per 24 hours to avoid desensitization
  • Can cause nausea, flushing
  • Do NOT combine with PDE5 inhibitors - risk of priapism
  • Can be given via subcutaneous injection or nasal spray

Supplies

  • Bacteriostatic water (2mL)
  • Insulin syringes
  • Alcohol swabs
  • Intranasal spray (alternative)

Related peptides

Calculate your PT-141 (Bremelanotide) dose in syringe units

Crestigen is an educational research reference. Nothing here is medical advice; many of these compounds are not approved for human use. Talk to a licensed clinician before using any substance.